Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. News
  7. Summary
    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
Delayed Australian Stock Exchange  -  02:10 2022-09-23 am EDT
278.14 AUD   -1.07%
09/22Australia shares hit over two-month low on Fed's stance; banks, tech stocks weigh
RE
09/14CSL presents new research and development center in Marburg, Germany
AQ
09/13CSL Inaugurates its New EUR 150 Million Research and Development Site on Grounds of Research Campus in Marburg's Görzhausen Industrial Park
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CSL Completes Vifor Pharma Acquisition

08/10/2022 | 05:11am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CSL LIMITED -1.07% 278.14 Delayed Quote.-4.33%
VIFOR PHARMA AG -0.28% 175.5 Delayed Quote.8.17%
All news about CSL LIMITED
09/22Australia shares hit over two-month low on Fed's stance; banks, tech stocks weigh
RE
09/14CSL presents new research and development center in Marburg, Germany
AQ
09/13CSL Inaugurates its New EUR 150 Million Research and Development Site on Grounds of Res..
CI
09/09Orphan Drug Designation granted for etranacogene dezaparvovec, CSL's gene therapy for h..
AQ
09/06CSL LIMITED : Ex-dividend day for final dividend
FA
09/01CSL : Shareholder Meeting Document
PU
09/01CSL : Annual Report 2022
PU
08/30CSL : Shareholder Meeting Document
PU
08/26Fitch Withdraws Vifor's Ratings on Acquisition by CSL
AQ
08/23Financial, healthcare stocks drag Australian shares to near three-week low
RE
More news
Financials (USD)
Sales 2023 13 290 M - -
Net income 2023 2 624 M - -
Net Debt 2023 10 763 M - -
P/E ratio 2023 33,3x
Yield 2023 1,35%
Capitalization 87 783 M 87 783 M -
EV / Sales 2023 7,41x
EV / Sales 2024 6,55x
Nbr of Employees 30 000
Free-Float 99,9%
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 182,04 $
Average target price 219,12 $
Spread / Average Target 20,4%
EPS Revisions
Managers and Directors
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
Andrew Nash Chief Scientific Officer, SVP & Head-Research
William Mezzanotte CMO, Executive VP, Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CSL LIMITED-4.33%87 783
SAMSUNG BIOLOGICS CO.,LTD.-14.73%38 653
BIOGEN INC.-17.56%28 700
WUXI BIOLOGICS (CAYMAN) INC.-49.86%25 210
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-31.77%19 085
BIOMARIN PHARMACEUTICAL INC.-3.97%15 736